{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 56,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/38",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.64,
        "x": 0.18,
        "y": 0.18
      },
      "kind": "image",
      "text": "Western blot panels for erlotinib, lapatinib, osimertinib, and ERAS-801",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97d0235c-edf1-4a7d-8f30-65a9779e680a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1 Kp,uu is a measure of the ratio of unbound brain concentration to unbound plasma concentration. Kim M, et al. Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice. Drug Metab. Dispos., 2019. PMID: 30705084",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b18a7fe-8187-4db7-98ce-406cd6d39ef0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.66,
        "x": 0.17,
        "y": 0.53
      },
      "kind": "table",
      "text": "Comparison table of compounds, companies, Kp brain, and Kp,uu brain values",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e762cb8-5dc9-4307-9661-8d3dd0f8a7db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "ERAS-801, a potent EGFRvIII/wt inhibitor with a Kp,uu over 4-fold higher than approved EGFR inhibitors, was specifically designed to inhibit EGFR in GBM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8ecf362-6c1e-4b66-bc8d-59ce3cf7933d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}